Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 2/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7856619 | 0.88 | CTSK (0.39) | TNFRSF1ATP53CTSK | |
| SCHEMBL4391183 | 0.85 | MAOB (0.40) | LPAR1TNFRSF1ACNR2GPR132CTSK | |
| SCHEMBL7858979 | 0.84 | MEN1 (0.49) | TNFRSF1ATP53CTSK | |
| SCHEMBL4389391 | 0.84 | FAAH (0.52) | TNFRSF1ACTSK | |
| SCHEMBL7848783 | 0.82 | CTSB (0.42) | TP53 | |
| SCHEMBL7857584 | 0.81 | CTSK (0.49) | CTSKL3MBTL1 | |
| SCHEMBL7858975 | 0.81 | CTDSP1 (0.46) | TP53CTSK | |
| SCHEMBL4391458 | 0.80 | MEN1 (0.44) | LPAR1CNR2GPR132CTSK | |
| SCHEMBL7856622 | 0.79 | NPC1 (0.47) | TNFRSF1ATP53CTSKL3MBTL1 | |
| SCHEMBL7856563 | 0.79 | LMNA (0.52) | TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | LPAR1 1990/4885TNFRSF1A 4433/4885CNR2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.